It has been suggested that Src tyrosine kinases are involved in the pathogenesis of renal fibrosis, and the selective Src tyrosinase inhibitor PP1 may inhibit fibrosis and have therapeutic potential for the treatment of CKD chronic kidney disease [70]. This evidence concerns the gene TYR and chronic kidney disease.